GlassScriptPhysician profile
Khushbir Singh Bath
NPI 1417204363
$6,282.26
in general payments reported to CMS, 2019-2025
27 companies · $2,512 in 2025
The $2,512 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,599 · 2024: $2,171 · 2025: $2,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,160 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,159.59 |
| Education | $122.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,309.25 | 2023-2025 | Rinvoq, Mavyret, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $823.64 | 2023-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $553.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $524.94 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $422.99 | 2024-2025 | |
| Genzyme Corporation | $346.82 | 2023-2025 | |
| Lilly USA, LLC | $342.24 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $341.08 | 2023-2025 | |
| Celgene Corporation | $292.83 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.71 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $240.74 | 2023 | Zeposia |
| Qol Medical, LLC | $176.23 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $147.45 | 2023-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $108.33 | 2025 | Terlivaz |
| Celltrion USA INC. | $67.40 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $61.02 | 2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.03 | 2023-2024 | Cyltezo |
| Ardelyx, INC. | $44.79 | 2023-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $34.81 | 2023-2024 | Linzess |
| Lucid Diagnostics INC. | $23.93 | 2024 | |
| Merck Sharp & Dohme LLC | $23.02 | 2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $22.46 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2024 | Simlandi |
| Braintree Laboratories, INC. | $15.44 | 2023 | Suflave |
| Olympus America INC. | $14.37 | 2023 | Visiglide |
| Intercept Pharmaceuticals, INC. | $14.20 | 2025 | |
| Intra-Sana Laboratories | $13.90 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khushbir Bath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.